ICON plc (NASDAQ: ICLR) rose about 3% Monday as traders leaned into a catalyst setup ahead of the company’s delayed fourth-quarter and full-year 2025 earnings release, which ICON has said it intends to publish on or before April 30, 2026. A recent analyst reset has also helped stabilize sentiment, including a March 26, 2026 price-target increase to $130 from BMO Capital.

ICON previously pushed back its Q4 and full-year 2025 reporting timeline while an audit committee investigation into accounting practices continues, and the company has communicated that it plans to release the results by (or before) April 30, 2026. Management has also indicated that full-year 2026 guidance is expected to be issued alongside those results, making the April deadline a focal point for investors assessing both fundamentals and credibility around reporting and controls.

The next major swing factor is whether ICON meets the April 30 reporting deadline and what it says about internal controls, any potential restatements, and the trajectory for bookings and demand in outsourced clinical research. With the stock still digesting the earlier investigation-related volatility, any clarity on timing, scope, and financial outlook could drive outsized moves in either direction into and after the filing.